Mirtsching et al Clin Breast Cancer 2011
Nab-paclitaxel: 1L trials
•
Phase II RCT: Nab-paclitaxel
125qw3/4
•
Total N=72 (all 1L)
•
HER2 negative (66.7%)
•
Primary endpoint: ORR (secondary: PFS, 1 and 2-yr survival, safety)
•
Median PFS (ITT) 14.5 mo (HER2 negative: 12.8 mo)
•
Median Survival 29 mo (HER2 negative: 27.3 mo)
•
In 1L MBC Nab-paclitaxel RR is about 40% depending on the schedule
